share_log

Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target

Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target

Needham重申对axsome therapeutics的买入评级,维持130美元的目标股价
Benzinga ·  2024/11/12 20:40  · 评级/大行评级

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

Needham 分析师Ami Fadia重申axsome therapeutics(纳斯达克:AXSM)为买入,并维持130美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发